Bivigam Market Report 2026

Bivigam Market Overview

• The Bivigam market growth in the historic period has been driven by clinical effectiveness of ivig, increased awareness of immunodeficiency disorders • Market expansion is supported by rising prevalence of immune disorders, expansion of neurological ivig applications • Growth Driver: Growing Prevalence Of Immunodeficiency Disorders Drives The Bivigam Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bivigam Market?

Bivigam is an intravenous immune globulin (IVIG) therapy used to treat primary humoral immunodeficiency (PI), a group of disorders where the immune system fails to produce sufficient antibodies to fight infections. It is derived from human plasma and provides a broad spectrum of antibodies to help strengthen the immune response in patients with PI. The main indication types of bivigam are primary immunodeficiency, chronic immune thrombocytopenia (ITP), secondary immunodeficiency, neurological disorders, and others. Primary immunodeficiency refers to a group of genetic disorders where the immune system is partially or completely impaired, making individuals more susceptible to infections, autoimmune diseases, and cancers. The formulations are intravenous (IV) solutions and subcutaneous (SC) solutions, and distribution channels include hospitals, specialty clinics, retail pharmacies, and online pharmacies. The various end users include adult, pediatric, and geriatric.

What Is The Bivigam Market Growth Forecast?

The growth in the forecast period can be attributed to rising prevalence of immune disorders, expansion of neurological ivig applications, growth of home infusion models, improved plasma supply chains, aging population trends. Major trends in the forecast period include rising adoption of ivig therapies, growing diagnosis of primary immunodeficiency, expansion of immunoglobulin use beyond pid, improved plasma collection and fractionation processes, increasing demand for long term immune support therapies.

Global Bivigam Market Segmentation

1) By Indication: Primary Immunodeficiency, Chronic Immune Thrombocytopenia (ITP), Secondary Immunodeficiency, Neurological Disorders, Other Indications 2) By Formulation: Intravenous (IV) Solution, Subcutaneous (SC) Solution 3) By Distribution Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies 4) By End User: Adult, Pediatric, Geriatric

What Are The Drivers Of The Bivigam Market?

The increasing prevalence of immunodeficiency disorders is expected to propel the growth of the bivigam market going forward. Immunodeficiency disorders refer to conditions where the immune system's ability to fight infections and diseases is compromised, either due to genetic factors or external influences such as infections or treatments. The prevalence of immunodeficiency disorders is rising due to increasing exposure to chronic diseases, as long-term illnesses weaken immune function and make individuals more vulnerable to infections. Bivigam enhances the management of immunodeficiency disorders by providing targeted immune support, making it ideal for patients with weakened immune systems. It helps prevent infections and improves overall immune function, supporting better patient health outcomes. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, there were 6,008 HIV diagnoses in England (including individuals previously diagnosed abroad) in 2023, marking a 51% rise from 3,975 cases reported in 2022. Therefore, the rising prevalence of immunodeficiency disorders will drive the bivigam industry. The rising healthcare expenditure is expected to drive the bivigam market going forward. Healthcare expenditure is growing due to advancements in medical technology, aging populations, rising prevalence of chronic diseases, and increased demand for quality care and personalized treatments. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances Bivigam adoption by improving access to immunoglobulin therapies, making it easier for patients with immunodeficiency disorders to receive timely treatment. It supports better disease management and overall patient health outcomes. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the bioclate (armour) market. The growing focus on personalized medicine is expected to boost the bivigam market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to the individual characteristics, needs, and genetic profile of each patient. The growing demand for personalized medicine is driven by advancements in genomics, targeted therapies, and the increasing prevalence of chronic diseases that require more precise treatment approaches. Personalized medicine enhances the use of Bivigam by tailoring its intravenous immunoglobulin therapy to meet individual patient needs, optimizing efficacy in managing primary humoral immunodeficiency. For instance, in February 2024, according to Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing focus on personalized medicine drives the bivigam industry.

Key Players In The Global Bivigam Market

Major companies operating in the bivigam market are ADMA Biologics Inc.

Regional Insights

North America was the largest region in the bivigam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Bivigam Market?

The bivigam market consists of sales of intravenous immune globulin (IVIG) therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bivigam Market Report 2026?

The bivigam market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bivigam industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.